BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 23034738)

  • 21. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample.
    Nosho K; Irahara N; Shima K; Kure S; Kirkner GJ; Schernhammer ES; Hazra A; Hunter DJ; Quackenbush J; Spiegelman D; Giovannucci EL; Fuchs CS; Ogino S
    PLoS One; 2008; 3(11):e3698. PubMed ID: 19002263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma.
    Ogino S; Odze RD; Kawasaki T; Brahmandam M; Kirkner GJ; Laird PW; Loda M; Fuchs CS
    Am J Surg Pathol; 2006 Sep; 30(9):1175-83. PubMed ID: 16931963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.
    Ogino S; Nosho K; Kirkner GJ; Kawasaki T; Meyerhardt JA; Loda M; Giovannucci EL; Fuchs CS
    Gut; 2009 Jan; 58(1):90-6. PubMed ID: 18832519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Chun HK; Lee WY; Park YS
    Med Oncol; 2010 Dec; 27(4):1277-85. PubMed ID: 19949897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.
    Lee S; Cho NY; Yoo EJ; Kim JH; Kang GH
    Arch Pathol Lab Med; 2008 Oct; 132(10):1657-65. PubMed ID: 18834226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
    Shiovitz S; Bertagnolli MM; Renfro LA; Nam E; Foster NR; Dzieciatkowski S; Luo Y; Lao VV; Monnat RJ; Emond MJ; Maizels N; Niedzwiecki D; Goldberg RM; Saltz LB; Venook A; Warren RS; Grady WM;
    Gastroenterology; 2014 Sep; 147(3):637-45. PubMed ID: 24859205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
    Ogino S; Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Kirkner GJ; Fuchs CS
    Int J Cancer; 2008 Jun; 122(12):2767-73. PubMed ID: 18366060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
    Nosho K; Shima K; Irahara N; Kure S; Firestein R; Baba Y; Toyoda S; Chen L; Hazra A; Giovannucci EL; Fuchs CS; Ogino S
    Mod Pathol; 2009 Jul; 22(7):922-32. PubMed ID: 19430421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.
    Jover R; Nguyen TP; Pérez-Carbonell L; Zapater P; Payá A; Alenda C; Rojas E; Cubiella J; Balaguer F; Morillas JD; Clofent J; Bujanda L; Reñé JM; Bessa X; Xicola RM; Nicolás-Pérez D; Castells A; Andreu M; Llor X; Boland CR; Goel A
    Gastroenterology; 2011 Apr; 140(4):1174-81. PubMed ID: 21185836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma.
    An C; Choi IS; Yao JC; Worah S; Xie K; Mansfield PF; Ajani JA; Rashid A; Hamilton SR; Wu TT
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):656-63. PubMed ID: 15701853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies.
    Ogino S; Cantor M; Kawasaki T; Brahmandam M; Kirkner GJ; Weisenberger DJ; Campan M; Laird PW; Loda M; Fuchs CS
    Gut; 2006 Jul; 55(7):1000-6. PubMed ID: 16407376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample.
    Ogino S; Kawasaki T; Kirkner GJ; Kraft P; Loda M; Fuchs CS
    J Mol Diagn; 2007 Jul; 9(3):305-14. PubMed ID: 17591929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer.
    Zlobec I; Bihl MP; Foerster A; Rufle A; Lugli A
    Histopathology; 2012 Nov; 61(5):777-87. PubMed ID: 22803799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX.
    Lee DW; Han SW; Cha Y; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Kang GH; Kim TY
    Clin Epigenetics; 2015; 7(1):63. PubMed ID: 26157509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer.
    Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Kirkner GJ; Dehari R; Meyerhardt JA; Fuchs CS; Ogino S
    Neoplasia; 2007 Jul; 9(7):569-77. PubMed ID: 17710160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
    Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
    J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.
    Min BH; Bae JM; Lee EJ; Yu HS; Kim YH; Chang DK; Kim HC; Park CK; Lee SH; Kim KM; Kang GH
    BMC Cancer; 2011 Aug; 11():344. PubMed ID: 21827707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
    Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY
    PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy.
    Lee DW; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Br J Cancer; 2013 May; 108(10):1978-84. PubMed ID: 23652310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.
    Goel A; Nagasaka T; Arnold CN; Inoue T; Hamilton C; Niedzwiecki D; Compton C; Mayer RJ; Goldberg R; Bertagnolli MM; Boland CR
    Gastroenterology; 2007 Jan; 132(1):127-38. PubMed ID: 17087942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.